IL268860A - Granzyme B inhibitor preparations and methods for preventing and/or treating blistered and/or peeling skin - Google Patents

Granzyme B inhibitor preparations and methods for preventing and/or treating blistered and/or peeling skin

Info

Publication number
IL268860A
IL268860A IL26886019A IL26886019A IL268860A IL 268860 A IL268860 A IL 268860A IL 26886019 A IL26886019 A IL 26886019A IL 26886019 A IL26886019 A IL 26886019A IL 268860 A IL268860 A IL 268860A
Authority
IL
Israel
Prior art keywords
granzyme
peeling
prevention
treatment
methods
Prior art date
Application number
IL26886019A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of IL268860A publication Critical patent/IL268860A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL26886019A 2017-02-28 2019-08-22 Granzyme B inhibitor preparations and methods for preventing and/or treating blistered and/or peeling skin IL268860A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762465055P 2017-02-28 2017-02-28
US201762611188P 2017-12-28 2017-12-28
PCT/CA2018/050230 WO2018157244A1 (en) 2017-02-28 2018-02-28 Granzyme b inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling

Publications (1)

Publication Number Publication Date
IL268860A true IL268860A (en) 2019-10-31

Family

ID=63369653

Family Applications (1)

Application Number Title Priority Date Filing Date
IL26886019A IL268860A (en) 2017-02-28 2019-08-22 Granzyme B inhibitor preparations and methods for preventing and/or treating blistered and/or peeling skin

Country Status (8)

Country Link
US (2) US20200016125A1 (enExample)
EP (1) EP3589304A4 (enExample)
JP (2) JP2020510655A (enExample)
KR (1) KR20190140907A (enExample)
AU (1) AU2018229079A1 (enExample)
IL (1) IL268860A (enExample)
MX (1) MX2019010230A (enExample)
WO (1) WO2018157244A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220332805A1 (en) * 2019-09-11 2022-10-20 University Of Cincinnati Treatment of Skin Blistering Diseases Using Antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016015160A1 (en) * 2014-08-01 2016-02-04 Vida Therapeutics, Inc. Cyclic urea compounds as granzyme b inhibitors
WO2017132771A1 (en) * 2016-02-03 2017-08-10 Vida Therapeutics, Inc. Granzyme b inhibitor formulations and methods for the treatment of burns

Also Published As

Publication number Publication date
EP3589304A1 (en) 2020-01-08
JP2020510655A (ja) 2020-04-09
AU2018229079A1 (en) 2019-10-10
JP2023062141A (ja) 2023-05-02
EP3589304A4 (en) 2020-11-25
KR20190140907A (ko) 2019-12-20
MX2019010230A (es) 2019-11-21
WO2018157244A1 (en) 2018-09-07
US20200016125A1 (en) 2020-01-16
US20230233526A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
IL277648A (en) Medical microbiota for the treatment and/or prevention of food allergy
IL273959A (en) Methods and preparations for the treatment of rare diseases
IL258741B (en) Combination of bcl-2 inhibitor and mek inhibitor for cancer treatment
SI3448421T1 (sl) Postopki in sestavki za preprečevanje in zdravljenje kirurških adhezij
IL264176B1 (en) Methods and preparations for the treatment of cancer
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
ES2856150T5 (en) Use of an inverse transcriptase inhibitor for the treatment and prevention of degenerative diseases
IL263563A (en) Compounds and methods for treating cancer
ZA201900984B (en) Methods and compositions for the treatment of warts
IL256675A (en) Methods and preparations for the prevention and treatment of pressure sores
IL264977B1 (en) Methods and preparations for treating melanoma
IL276905A (en) Treatment and prevention of preeclampsia
GB201605127D0 (en) Composition and methods of treatment
PL3758799T3 (pl) Kompozycja do zapobiegania i traktowania uszkodzeń skóry spowodowanych fotoekspozycją
SG11202000724XA (en) Methods and compositions for the treatment of cancer
EP3616705A4 (en) COMPOSITION WITH AMOMUM VILLOSUM TO IMPROVE THE PREVENTION AND TREATMENT OF FATTY LIVER
ES3065815T3 (en) Compositions for the prevention and treatment of acute renal injury
IL280262A (en) Compositions and methods for treating cancer
HUE040273T2 (hu) Termékek rozsdamentes acél preventív kezelésére és ezekkel kapcsolatos eljárások
GB201617715D0 (en) Methods for the treatment and prevention of ebola
SG11201708214UA (en) Combination of at least one protease inhibitor and at least one active principle for use in the prevention and/or treatment of skin lesions
HK40014143A (zh) 预防和/或治疗心血管疾病的组合物
GB201810925D0 (en) Compositions and methods of treatment
GB201815694D0 (en) Prevention and treatment of cancer
HK40006311A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders